Press Release : European Commission approves -2-

   [1] O'Shaugnessy J, et al. Patient (pt) preference for the 
pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH 
FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of 
the open-label, randomised crossover PHranceSCa study. Presented at ESMO, 
2020 Sept 19-21. Abstract #165MO. 
 
   [2]  Xavier P, et al. Preference for subcutaneous or intravenous 
administration of trastuzumab in patients with HER2-positive early 
breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 
2013;14(10):962-70. 
 
   [3] Tjalma, et al. Trastuzumab IV versus SC: A time, motion and cost 
assessment in a lean operating day care oncology unit. Presented at: 
SABCS; 2016 Dec 6-10; San Antonio, TX, USA. Abstract #P4-21-15. 
 
   [4] US Food and Drug Administration. Prescribing information for Phesgo. 
[Internet; cited December 2020]. Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. 
 
 
   [5] US Food and Drug Administration. Prescribing Information for 
Herceptin. [Internet; cited December 2020]. Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/. 
 
   [6] US Food and Drug Administration. Prescribing information for 
Perjeta. [Internet; cited December 2020]. Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125409lbl.pdf. 
 
 
   [7] Tan A. et al. Subcutaneous administration of the fixed-dose 
combination of trastuzumab and pertuzumab in combination with 
chemotherapy in HER2-positive early breast cancer: Primary analysis of 
the phase III, multicenter, randomized, open-label, two-arm FeDeriCa 
study. Presented at SABCS; 2019 Dec 10-14; San Antonio, Texas. Abstract 
#PD4-07. 
 
   [8] Sripada et al. Subcutaneous fixed-dose combination of pertuzumab and 
trastuzumab for the treatment of metastatic breast cancer in Canada - a 
budget impact analysis. Presented at SABCS; 2020 Dec 08-11; San Antonio 
Texas: PS9-55. 
 
   [9] Roche data on file. 
 
   [10] Clinical trials.gov. A Study to Evaluate the Pharmacokinetics, 
Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose 
Combination of Pertuzumab and Trastuzumab in Combination With 
Chemotherapy in Participants With HER2-Positive Early Breast Cancer 
(FeDeriCa). [Internet: December 2020]. Available from: 
https://clinicaltrials.gov/ct2/show/NCT03493854. 
 
   [11] Halozyme. Enhanze(R) Drug Delivery Technology. [Internet; cited 
December 2020]. Available from: 
https://www.halozyme.com/enhanze/overview/default.aspx. 
 
   [12] Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) 
in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 
2014;2014:852748. 
 
   [13] Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and 
discovering ERBB3. Nat Rev Cancer 2009;9:463-75. 
 
   [14] Gianni L, et al. Efficacy and safety of neoadjuvant pertuzumab and 
trastuzumab in women with locally advanced, inflammatory, or early 
HER2-positive breast cancer (NeoSphere): a randomised multicentre, 
open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32. 
 
   [15] Minckwitz G, et al. Adjuvant Pertuzumab and Trastuzumab in Early 
HER2-Positive Breast Cancer. N Engl J Med. 2017;13;377(2):122-31. 
 
   [16] Swain SM, et al. Pertuzumab, trastuzumab, and docetaxel in 
HER2-positive metastatic breast cancer. N Engl J Med. 
2015;19;372(8):724-34. 
 
   [17] Jarrett A, et al. Experimentally-driven mathematical modelling to 
improve combination targeted and cytotoxic therapy for HER2+ breast 
cancer. Sci Rep. 2019;9:12830. 
 
 
 
   Roche Group Media Relations 
 
   Phone: [phone] / e-mail: 
https://www.globenewswire.com/Tracker?data=-1jHfHsZsNiiBnXaKNpUgJvCJpIRJppO8mp72WmZXUpJ-sNkJdyAc1rNBQRTNyyUUPUew4epixwtD3ZFuQWnBtSXT-YvXrxfgwhmJZ45rFX8Jah67AOdNxprRSN_8pm- 
[e-mail] 
 
 
 
 
 
 
 
 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: [phone]     Phone: [phone] 
Dr. Daniel Grotzky          Karsten Kleine 
 Phone: [phone]     Phone: [phone] 
Nina Mählitz           Nathalie Meetz 
 Phone: [phone]     Phone: [phone] 
Dr. Barbara von Schnurbein 
 Phone: [phone] 
 
 
 
 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]          e-mail: mailto:[e-mail] 
 [e-mail]                         [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]   e-mail: mailto:[e-mail] 
 [e-mail]                  [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]       e-mail: mailto:[e-mail] 
 [e-mail]                      [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
Investor Relations North America 
Loren Kalm                                    Dr. Lisa Tuomi 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]            e-mail: mailto:[e-mail] 
 [e-mail]                           [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
 
 
   Attachment 
 
 
   -- 23122020_MR_Phesgo EU approval 
      https://ml-eu.globenewswire.com/Resource/Download/f3488fa0-1527-4b11-ac68-6443eb1a3767

(END) Dow Jones Newswires

December 23, 2020 01:00 ET (06:00 GMT)